Understanding how the Body Responds to Weight Loss Medications
This study wants to better understand how people respond to nutrient stimulated hormone receptor agonist (NuSH RA) medications like semaglutide (Wegovy) and tirzepaide (Zepbound).
Why this Research Matters
NuSH RA medicines, like Wegovy and Zepbound, are new treatments for obesity that can help people lose weight. But they do not work the same for everyone. We want to learn why people respond differently so we can find better ways to help with weight loss.
What to Expect
You may join this study, if you plan to take a NuSH RA medicine like Wegovy or Zepbound to help with weight loss. If you join, we will measure your weight, height, waist size, and blood pressure. You will also have DXA scans, which are a type of X-ray that measure body fat, muscle, and bone density. You will provide blood and stool samples, so we can learn about your health and gut microbiome. You will also wear an activity monitor on your wrist and fill out several online surveys about how often you are taking your medicine, how active you are, how well you sleep, and your eating habits.
Study Duration
You will be in the study for about 14 months. You will have three in-person visits, each lasting about 1 to 1½ hours. Your first visit will be around the time you begin taking your NuSH RA medication, and two follow-up visits will be about 6 and 12 months later.
Who can Participate
You many be able to join this study if you:
- Are between 18 and 65 years old
- Have overweight or obesity
- Are currently a patient at, or are planning to schedule a new patient visit at the CU Medicine Weight Managment Clinic
- Plan to take a NuSH RA medication (such as Wegovy or Zepbound) for weight loss and can get the medicine through insurance or by paying for it yourself
Study ID
Protocol Number: 25-2231
Compensation Information
Meet the Team
Principal Investigator